BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 23848221)

  • 1. In vivo characterization of the highly selective monoacylglycerol lipase inhibitor KML29: antinociceptive activity without cannabimimetic side effects.
    Ignatowska-Jankowska BM; Ghosh S; Crowe MS; Kinsey SG; Niphakis MJ; Abdullah RA; Tao Q; O' Neal ST; Walentiny DM; Wiley JL; Cravatt BF; Lichtman AH
    Br J Pharmacol; 2014 Mar; 171(6):1392-407. PubMed ID: 23848221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective monoacylglycerol lipase inhibitors: antinociceptive versus cannabimimetic effects in mice.
    Ignatowska-Jankowska B; Wilkerson JL; Mustafa M; Abdullah R; Niphakis M; Wiley JL; Cravatt BF; Lichtman AH
    J Pharmacol Exp Ther; 2015 May; 353(2):424-32. PubMed ID: 25762694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Full Fatty Acid Amide Hydrolase Inhibition Combined with Partial Monoacylglycerol Lipase Inhibition: Augmented and Sustained Antinociceptive Effects with Reduced Cannabimimetic Side Effects in Mice.
    Ghosh S; Kinsey SG; Liu QS; Hruba L; McMahon LR; Grim TW; Merritt CR; Wise LE; Abdullah RA; Selley DE; Sim-Selley LJ; Cravatt BF; Lichtman AH
    J Pharmacol Exp Ther; 2015 Aug; 354(2):111-20. PubMed ID: 25998048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The monoacylglycerol lipase inhibitor KML29 with gabapentin synergistically produces analgesia in mice.
    Crowe MS; Wilson CD; Leishman E; Prather PL; Bradshaw HB; Banks ML; Kinsey SG
    Br J Pharmacol; 2017 Dec; 174(23):4523-4539. PubMed ID: 28963716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative biochemical characterization of the monoacylglycerol lipase inhibitor KML29 in brain, spinal cord, liver, spleen, fat and muscle tissue.
    Pasquarelli N; Porazik C; Hanselmann J; Weydt P; Ferger B; Witting A
    Neuropharmacology; 2015 Apr; 91():148-56. PubMed ID: 25497453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of the endocannabinoid-regulating enzyme monoacylglycerol lipase elicits a CB
    Owens RA; Mustafa MA; Ignatowska-Jankowska BM; Damaj MI; Beardsley PM; Wiley JL; Niphakis MJ; Cravatt BF; Lichtman AH
    Neuropharmacology; 2017 Oct; 125():80-86. PubMed ID: 28673548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repeated low-dose administration of the monoacylglycerol lipase inhibitor JZL184 retains cannabinoid receptor type 1-mediated antinociceptive and gastroprotective effects.
    Kinsey SG; Wise LE; Ramesh D; Abdullah R; Selley DE; Cravatt BF; Lichtman AH
    J Pharmacol Exp Ther; 2013 Jun; 345(3):492-501. PubMed ID: 23412396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following cisplatin treatment.
    Guindon J; Lai Y; Takacs SM; Bradshaw HB; Hohmann AG
    Pharmacol Res; 2013 Jan; 67(1):94-109. PubMed ID: 23127915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain.
    Kinsey SG; Long JZ; O'Neal ST; Abdullah RA; Poklis JL; Boger DL; Cravatt BF; Lichtman AH
    J Pharmacol Exp Ther; 2009 Sep; 330(3):902-10. PubMed ID: 19502530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of monoacylglycerol lipase attenuates nonsteroidal anti-inflammatory drug-induced gastric hemorrhages in mice.
    Kinsey SG; Nomura DK; O'Neal ST; Long JZ; Mahadevan A; Cravatt BF; Grider JR; Lichtman AH
    J Pharmacol Exp Ther; 2011 Sep; 338(3):795-802. PubMed ID: 21659471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In Vivo Characterization of the Ultrapotent Monoacylglycerol Lipase Inhibitor {4-[bis-(benzo[d][1,3]dioxol-5-yl)methyl]-piperidin-1-yl}(1H-1,2,4-triazol-1-yl)methanone (JJKK-048).
    Aaltonen N; Kedzierska E; Orzelska-Górka J; Lehtonen M; Navia-Paldanius D; Jakupovic H; Savinainen JR; Nevalainen T; Laitinen JT; Parkkari T; Gynther M
    J Pharmacol Exp Ther; 2016 Oct; 359(1):62-72. PubMed ID: 27451409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolonged monoacylglycerol lipase blockade causes equivalent cannabinoid receptor type 1 receptor-mediated adaptations in fatty acid amide hydrolase wild-type and knockout mice.
    Schlosburg JE; Kinsey SG; Ignatowska-Jankowska B; Ramesh D; Abdullah RA; Tao Q; Booker L; Long JZ; Selley DE; Cravatt BF; Lichtman AH
    J Pharmacol Exp Ther; 2014 Aug; 350(2):196-204. PubMed ID: 24849924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spinal administration of the monoacylglycerol lipase inhibitor JZL184 produces robust inhibitory effects on nociceptive processing and the development of central sensitization in the rat.
    Woodhams SG; Wong A; Barrett DA; Bennett AJ; Chapman V; Alexander SP
    Br J Pharmacol; 2012 Dec; 167(8):1609-19. PubMed ID: 22924700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The endocannabinoid hydrolysis inhibitor SA-57: Intrinsic antinociceptive effects, augmented morphine-induced antinociception, and attenuated heroin seeking behavior in mice.
    Wilkerson JL; Ghosh S; Mustafa M; Abdullah RA; Niphakis MJ; Cabrera R; Maldonado RL; Cravatt BF; Lichtman AH
    Neuropharmacology; 2017 Mar; 114():156-167. PubMed ID: 27890602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The monoacylglycerol lipase inhibitor JZL184 suppresses inflammatory pain in the mouse carrageenan model.
    Ghosh S; Wise LE; Chen Y; Gujjar R; Mahadevan A; Cravatt BF; Lichtman AH
    Life Sci; 2013 Mar; 92(8-9):498-505. PubMed ID: 22749865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contrasting effects of selective MAGL and FAAH inhibition on dopamine depletion and GDNF expression in a chronic MPTP mouse model of Parkinson's disease.
    Pasquarelli N; Porazik C; Bayer H; Buck E; Schildknecht S; Weydt P; Witting A; Ferger B
    Neurochem Int; 2017 Nov; 110():14-24. PubMed ID: 28826718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The fatty acid amide hydrolase (FAAH) inhibitor PF-3845 acts in the nervous system to reverse LPS-induced tactile allodynia in mice.
    Booker L; Kinsey SG; Abdullah RA; Blankman JL; Long JZ; Ezzili C; Boger DL; Cravatt BF; Lichtman AH
    Br J Pharmacol; 2012 Apr; 165(8):2485-96. PubMed ID: 21506952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Δ9-tetrahydrocannabinol and endocannabinoid degradative enzyme inhibitors attenuate intracranial self-stimulation in mice.
    Wiebelhaus JM; Grim TW; Owens RA; Lazenka MF; Sim-Selley LJ; Abdullah RA; Niphakis MJ; Vann RE; Cravatt BF; Wiley JL; Negus SS; Lichtman AH
    J Pharmacol Exp Ther; 2015 Feb; 352(2):195-207. PubMed ID: 25398241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Selective Monoacylglycerol Lipase Inhibitor MJN110 Produces Opioid-Sparing Effects in a Mouse Neuropathic Pain Model.
    Wilkerson JL; Niphakis MJ; Grim TW; Mustafa MA; Abdullah RA; Poklis JL; Dewey WL; Akbarali H; Banks ML; Wise LE; Cravatt BF; Lichtman AH
    J Pharmacol Exp Ther; 2016 Apr; 357(1):145-56. PubMed ID: 26791602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of endocannabinoid catabolic enzymes elicits anxiolytic-like effects in the marble burying assay.
    Kinsey SG; O'Neal ST; Long JZ; Cravatt BF; Lichtman AH
    Pharmacol Biochem Behav; 2011 Mar; 98(1):21-7. PubMed ID: 21145341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.